Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG: 1349)

Market Cap	5.75B
Revenue (ttm)	790.86M
Net Income (ttm)	118.91M
Shares Out	1.04B
EPS (ttm)	0.11
PE Ratio	15.17
Forward PE	n/a
Dividend	0.04 (2.46%)
Ex-Dividend Date	Aug 26, 2024

Volume	192,000
Open	1.780
Previous Close	n/a
Day's Range	n/a
52-Week Range	1.700 - 2.660
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast can...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 948
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1349

Financial Performance

In 2023, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s revenue was 850.73 million, a decrease of -17.50% compared to the previous year's 1.03 billion. Earnings were 108.63 million, a decrease of -21.28%.

Financial numbers in CNY